MaxiNovel Disclosed the Study Results of Orally Active PD-1/PD-L1 Inhibitors at 2018 AACR

GUANGZHOU, China--()--MaxiNovel Pharmaceuticals, Inc. presented for the first time the preclinical results of its orally active PD-1/PD-L1 inhibitors either as a single agent or in combo studies. The key findings are as follow:

“we are encouraged by the study results and excited about the small molecules targeting PD-1/PD-L1 pathway. We are looking forward to the orally active drugs to be added to today’s antibody only therapy.”

  • As a single agent in a MC38 model, the MaxiNovel compound (120 mpk) showed similar TGI and ratio of CD8+/Treg to that of aPD-1 Ab (200 μg) reported by BMS group (PLoS One. 2016 Nov 18;11(11): e0167251)
  • In the combination study in a MC38 model, the MaxiNovel compound (30 mpk) demonstrated statistically significant combo efficacy with Celebrex, Cisplatin, Epacadostat and aCTLA-4 Ab.
  • In the combination study in a 4T1 model, the MaxiNovel compound (30 mpk) in combination with aCTLA-4 Ab had similar survival ratio as that of aPD-1Ab/aCTLA-4 Ab combination reported by researchers from Australia and US (Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9)

“While IO combination is the industrial trend, the ultimate success will be dependent on the safety of various combinations,” commented Dr. David Moore, MaxiNovel’s SVP of DMPK and Drug Safety. "These orally active small molecule PD-1/PD-L1 inhibitors will provide more flexibility for dose and safety adjustment in the combination with various drugs. Maxinovel has demonstrated statistically significant efficacy of two-component combination with excellent safety in various tumor models. Future goals will be to conduct three, four or even more component combinations, perhaps in a single oral pill.”

Dr. Zujun Li, the Clinical Associate Professor of Medicine at New York University and the PI for immunotherapy clinical trials echoed “we are encouraged by the study results and excited about the small molecules targeting PD-1/PD-L1 pathway. We are looking forward to the orally active drugs to be added to today’s antibody only therapy.”

About MaxiNovel Pharmaceuticals, Inc:

Maxinovel Pharmaceuticals, Inc. is a biotech company focusing on the discovery and development of Immuno-oncology therapy and targeted therapy. It will use its orally active Immuno-oncology product platform to bring effective combo product of multi-components in a single oral pill to the patients worldwide. For more info: www.maxinovel.com

Contacts

MaxiNovel Pharmaceuticals, Inc.
Ms. Pingjing Zhang
pjzhang@maxinovel.com

Recent Stories

RSS feed for MaxiNovel Pharmaceuticals, Inc.